Orchard Therapeutics is a holding company. Through its subsidiaries, Co. is a gene therapy company focused on the development of potentially curative gene therapies. Co.'s programs focused on neurodegenerative disorders consist of its commercial program approved in Europe, Libmeldy (OTL-200) for metachromatic leukodystrophy, two clinical proof of concept-stage programs, OTL-203 for mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, and three preclinical programs, OTL-202 for mucopolysaccharidosis type IIIB, OTL-204 for frontotemporal dementia with progranulin mutations and OTL-205 for amyotrophic lateral sclerosis. The ORTX stock yearly return is shown above.
The yearly return on the ORTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ORTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|